iii

Size: px
Start display at page:

Download "iii 4 3 100 4 1 100 4"

Transcription

1 The real voyage of discovery consists not in seeking new landscapes, but in having new eyes. Marcel Proust

2 iii

3 iv

4 v iii EBM cure care

5 vi BSE

6 vii

7

8 A 1 A A A =

9 2 1 = = (1) (2) (3) 3 (1) A (2) (3)

10 A 5 6 A A A 1 A A 2 4

11 4 1 A 4 10 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) A 1.1

12 : 100 m 50m 20m

13 : = = = 1.3 1

14 1.3 7 A 1 1.3

15 : 2

16 C

17 kg 2 3 NOVA S C C 6

18 X X X Y X Y X Y X Y

19

20 : = = 50 B

21 14 1 B B B B B B B B B

22 B B B 1980 B B

23 16 1 B B B B B B B

24 Yahoo! JAPAN TBS TBS A B C

25 [1] [2] [3] [4] [5] bunretu/

26 19 2 EBM Evidence Based Medicine 2.1 IC IC [1] IC IC IC 400

27 IC 1914 assault IC IC 1964 IC IC

28 IC IC IC 19 2 IC IC 1990 IC IC IC IC (1) (2) IC IC 2.1 IC IC IC IC

29 22 2 IC (1) (2) IC IC 3 3 IC IC IC Quality of Life QOL IC IC IC IC IC

30 IC IC IC second opinion CT 4 2

31

32

33 %

34 : 1999 % % 33.3 % 40 50

35

36 :

37

38

39 truth telling

40 [9] % 1

41 % 54.7 % 35.5 % 43.8 % %

42 A: B: C: D: A E: F: G: A: B: C: D: A E: F: G: A: B: C: D: A E: F: G: 2.3: 2 2.1

43 : (%) (%)

44 % 77 % 81 % 74 % 8 74 % 65 % % 27 % 27 % 27 % 47 % 23 %

45 : I Can Cope Program I Can Cope Cope

46

47 EBM

48 2.6 EBM EBM EBM evidence DNA EBM DNA EBM EBM EBM evidence EBM evidence evidence EBM EBM EBM 4 7

49 McMaster Guyatt Evidence Based Medicine EBM Guyatt EBM Working Group JAMA User s Guide Workshop Guyatt EBM Sackett McMaster Oxford EBM 1997 EBM 1996 EBM EBM EBM EBM 1 EBM EBM 2 Evidence MEDLINE 3 4 EBM EBM EBM EBM EBM

50 DNA = DNA DNA A T C G 4 2 DNA 99.9 % 0.1 % DNA DNA X DNA Y SNP SNP SNP DNA 1998 HER2 HER2 HER2 HER2 HER2

51 44 2 SNP EBM EBM EBM A B2 A B EBM A A A B EBM EBM SNP SNP SNP

52

53 advance directive 1) 2) 1) vol 7, No 1,

54 HMO

55

56 CT MRI 10 right duty

57 [1] 1994 [2] Vol. 13 No [3] informed consent: IC [4] [5] tokiyasu/ronbun/tokiyasu_02.html [6] ushijima/be_info/thema/ [7] [8] 1989 [9] vol. 4 No [10] 1994 [11] BP [12] 1989 [13] 1989 [14] 1993 [15] 1997 [16] 1994 [17] 1994 [18]

58 Web

59 : % : : 1

60 % % % % % Visiting Assistant Professor Department of Physiology & Biophysics

61 % intervention DNA

62 SNP 10 CT MRI single nucleotide polymorphism DNA 1 11

63 cure care

64 3.3 cure care IBS 14 TEG

65 EMA Ecologically Momentary Asessment EMA EMA cure care cure care 1 cure care cure care care cure

66 3.3 cure care K

67 60 3 care cure care cure care cure care cure care

68 SLE γ SLE 5 50 %

69 T T HLA % SNP 26 SNP

70 SLE 10 3

71 NIH

72

73 66 3 gynecology gyne HIV

74 CT 100 % %

75 % 50 % 90 % QOL g % 32 quality of life

76

77 molecular biology 10 DNA 30 CT CT MRI 34 DC neuroblastoma 35

78 molecular biology bp 500 bp cdna 3000 bp

79 field 8 1 / / 3 1 /

80 β

81 % % % %

82 : % % 14.6 % 11.7 % 7.5 % 33.5 % 11.7 % 9.1 %

83 :

84 ADL

85

86 Standard liver volume 44 US guided PTC 45 PTGBD 46 US guided PTC PTGBD = ) Standard liver volume ) 45 46

87 Thomas Stazl Bismuth Pichlmayr 1 2 Rogier HPD NIH DNA DNA 50 National Institutes of Health

88 %

89 mortality % 2 3% 2 3%

90 SARS

91

92 WHO

93 stem cell disuse syndrome 62

94 PC

95 PC PC PC AI 63 5 ICOT 1990 CT 1994 PC artificial intelligence

96 PC SNP 64 clinical bioinformatics PC 10 AI X 64 55

97 C % 1% % OK

98 BST 65 65

99 BST

100 QOL 70 QOL QOL 70 quality of life QOL

101 QOL QOL

102 =

103 96 3 PTSD

104 PET 72 fmri 73 SQUID MRI PET MRI 74

105

106 in silico human in silico human

107 100 3 E-Cell 30 in silico human

108 BP RNA 30 WHO NHK X 80 WHO RNA RNA RNA DNA

109 % : WHO WHO 99 % 82

110 OPV IPV IPV OPV IPV OPV IPV 2 RNA 83 oral poliovaccine 84 inactivated poliovaccine

111 104 3

112 X 1895 X DNA RNA DNA DNA intermentional radiology X CT

113 CT DNA 1975 NMR 1975 PET PTCA WHO 1980 MRI AIDS CCD 1985 PCR O PTCA SARS

114 Y=48,000 Y=218,000

115 108 4 Y=15,000 H 2 O

116 H 2 O H 3 O + H 3 O + (H 2 O) n NH + 4 NH + 4 (H 2 O) n O 2 (CO 3 ) (NO 3 ) (OH ) NO 3 (HNO 3 ) m (H 2 O) n HNO 3 3 /cm

117 110 4 DNA

118 % % 3 98 % + ADP + H + + ATP ATP ADP ATP 1 ADP ATP ATP ADP ATP ATP ATP 30 % 1

119 mg ppm % µg µg 8

120

121 A 3 A placebo I shall please QOL

122 CM 3

123 SARS MMR 1 2 2

124 MMR

125 BCG DTP DTP WHO 1981 DTP MMR MMR DPT A B Weil BCG [ ] [ ] DPT [ ] 1981

126 [ ] 10 % [ ] [ ] [ ] % [ ] 1 6% % [ ] [ ] [ ] [ ] 1 [ ] ADM [ ] % [ ] [ ] % 2 10 % [ ] [ ] [ ]

127 120 4 [ ] DPT B [ ] [ ] BSE BSE BSE BSE BSE BSE BSE bovine spongiform encephalopathy BSE BSE

128 4.3 BSE 121 BSE 1 BSE 2 3% BSE prion proteinaceous infectious particle proin o i S DNA RNA BSE : scraping

129 122 4 Creutzfeldt Jakob disease CJD 1920 CJD CJD 3 CJD CJD 10 % CJD CJD CJD CJD CJD 3 CJD BSE 1996 CJD variant CJD vcjd CJD vcjd 29 vcjd 1 CJD : CJD vcjd vcjd CJD CJD BSE 1996

130 4.3 BSE 123 BSE BSE BSE BSE 1 vcjd CJD CJD BSE vcjd BSE CJD vcjd BSE 2 vcjd CJD BSE vcjd BSE CJD vcjd BSE 100 % 4.3: BSE BSE vcjd BSE vcjd 1 vcjd BSE BSE vcjd BSE BSE 500

131 124 4 vcjd vcjd vcjd vcjd vcjd CJD vcjd BSE 1986 BSE BSE 1988 EU EU BSE BSE BSE BSE BSE 5 BSE

132 4.3 BSE 125 BSE BSE BSE BSE 1990 BSE BSE 1991 WHO BSE BSE BSE CJD BSE 1996 BSE CJD BSE BSE BSE EU 4 3 EU EU 1990 BSE EU 1990 EU 1990 BSE BSE EU BSE

133 BSE BSE BSE BSE 40 BSE EU EU EU EU BSE BSE 1991 BSE BSE BSE EU BSE vcjd BSE vcjd BSE BSE BSE BSE OIE / / 1000 BSE 100

134 4.3 BSE 127 vcjd vcjd 134 BSE 2 vcjd vcjd 2000 BSE 75 BSE 1 vcjd BSE 100 vcjd vcjd BSE BSE MRM vcjd vcjd BSE 1 BSE BSE 1 BSE 1 2 3

135 BSE BSE 2 BSE 0% 1 2 BSE 1 vcjd MRM vcjd BSE BSE BSE BSE vcjd BSE 2 BSE BSE EU BSE 1996 BSE WHO BSE

136 4.3 BSE % BSE EU 2001 EU BSE 3 BSE BSE BSE EU BSE BSE BSE BSE BSE BSE 9 10 BSE BSE BSE BSE EU BSE 3. 1 EU BSE

137 130 4 BSE O157 BSE : vcjd BSE BSE BSE BSE 22 vcjd BSE

138 4.3 BSE 131 BSE vcjd vcjd EZTV vcjd BSE 2 3 BSE

139 132 4 BSE mad cow disease BSE vcjd = % BSE % 1 BSE 1 BSE 9 10 BSE BSE

140 4.3 BSE BSE BSE BSE 2 3 BSE BSE BSE vcjd BSE BSE

141 BSE BSE BSE BSE BSE vcjd vcjd 150

142 4.3 BSE BSE

143 136 4 vcjd BSE BSE BSE DNA

144 4.3 BSE 137 DNA biological vcjd ELISA BSE BSE

145 138 4 vcjd ELISA ELISA 10 BSE BSE BSE BSE

146 4.3 BSE 139 BSE BSE CJD BSE BSE vcjd BSE BSE

147 140 4 BSE NHK BSE BSE BSE 18 BSE vcjd 130 SARS SARS BSE BSE 5 6 BSE vcjd 100 % 100 % 100 %

148 4.3 BSE 141 BSE BSE BSE BSE

149 142 4 Priority BSE BSE: Bovine Spongiform Encephalopathy BSE vcjd: variant Creutzfeldt-Jakob disease BSE BSE vcjd BSE vcjd BSE BSE HIV CJD BSE BSE Web BSE 5 31

150 4.3 BSE 143 BSE BSE 4.3 BSE

151 BSE BSE vcjd

152 media literacy media literacy media literacy media literacy entertainment education entertainment education media literacy media literacy media literacy media literacy

153 146 4 media literacy 4 [1] 2002 [2] 2002 [3] 2000 [4] 2001 [5] 2001 [6] 2003 [7] [8] WHO, [9] CDC, [10] [11] [12] [13] [14] [15] 2002 [16] NHK 2002 [17] 1998 [18] 2001 [19] BSE [20] 1998 [21] [22] DrYosikawa/DrYoshi2003/ [23] [24] 2002 [25] 2002

154 [26] [27] 2002 [28] [29] Center for Disease Control and Prevention, [30] Hollywood Health & Society, [31] Arbind Singhal and Everett M. Rogers. Entertainment-Education; A communication Strategy for Social Change [32] [33] e-learning site: index.php

155

156

157

158 PL 1 DRG/PPS

159 152 5

160 153 6 Z

161 % % 500

162 Z 10 Z Z 40 A %

163 A 50 B B

164 Q1. Q2. Q3. Q4. 1 Q5. Q6. Q7. Q8. MR Q9. MR Q10. Q11. Q12. Q13. Q14. Q1 16 Q2 Q7 16

165 Q8 Q9 MR Medical Representative MR MR MR Q8 MR MR Q9 MR MR Q2 Q7 MR Z MR MR MR MR Q10 Q11 15

166 MR Q10 Q11 Q12 Q

167 160 6 Q13 Q13 Q14 6.3

168 Drug Information BP 20 1 DI 6.4 Q15. Q

169 162 6 Q17. Q18. Q19. Q20. Q19 Q21. Q % Q16 Q17 Q16 Q18 Q17 Q17 Q16 Q17 Q18 Q20 2 6

170 Q

171

172 % Q1. Q Q3. 0 Q4. 1 Q Q Q Q8. MR Q9. MR Q Q Q Q Q Q Q Q Q18.

173 Q Q Q Q Q23.

174 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Q16 Q17 Q18 Q19 Q20 Q21 6.1: 5 Q8 Q14 Q16 Q21 5: 4: 3: 2: 1: Q8. MR Q9. MR Q10. Q11. Q12. Q13. Q14. Q16. Q17. Q18. Q19. Q20. Q19 Q21.

175

176

177 / / / / / / / %

178

179 ( )

180 : 8

181 /

182 EBM 1 2

183 % % % %

184

185 specific intensive

186

187

188 effort time

189

190

191

192 PSA PSA PSA watchfull waiting

193 186 8 ED DHEA

194

195 PET 8 PET PET PET PET PET PET PET PET PET

196 QOL GDP 7 14

197 A B A

198 PET GDP

199

200 QOL Quality Of Life EBM Evidence Based Medicine 2. IT IT 5.

201 ID

202 GDP GDP

203 ICU CCU MRI

204 SNP

205

206 Blu

207 Rosso

208

209

210 HIV X Y Communication H X 1 A X 2 A,Y A B A C B 58 6 A 42 Y B A B C A A X B A H B A B Y

211 204 9 B C B A C A B C B C S X A Y A B C B D A 7 A B C A A A X Y A 12 A 1 5 A D A A B,C B Y 1. B 2. B D

212 X D X B D H X A Y A B Y B A A Y B A A B A A 3 22 B A 3 18 A B A B X B A Y 1. B A A 2. A B B 3

213 206 9 Communication Communication ADR Alternative Dispute Resolution S X,Y,Z,A,B, X Y 45 Y A 6 X A Z B 9 9 B X Y X B 709 Y Z 715 X

214 A X B B X 3. 1% B X H X,Y X Y X X 3 3 X 0.06 X

215 % S X:A,E,F,B, Y:H 1971 H A B 2 E F H F A B E F A B E A F H A E F B H

216 : 3. : 4. : S S X:,Y: 2. X:

217 ,Y: S X: 16,Y:

218 Y S Y:, P:, A: P A Y Y

219 % S X,Y, Z,W,V X cc 3% 100cc 9 30 Y X Y Y Z Z

220 W V 2 2 W X Y W X Y W W X Y S

221 214 9 X,Y, Z,W,V X cc 3% 100cc 9 30 Y X Y Y Z Z W V 2 2 W X Y W X Y 1. 2.

222 W W X Y S X X (a) (b)

223 (a) (b) (a) 645 (b)

224 S X, Y X 26 6 X X X 6 2 X H

225 218 9 H Y Y Y Y Y a Y b Y 8 35 KCL 8 46 c (c) 199 (a)(b) c c a b c

226 (a) (b) (c)

227 220 9 H X,S,Y,T,N X S S Y X S 8 34 T K 8 48 N X 6 50 T T X T T X 2. T T T 3. T K X T

228 H Y, A,B A,B X 56 A Y Y X A B X X A,B X Y 58 X A B X A,B 1. Y 2. Y A 3. Y A,B X Y Y A,B 1 Y 2 X Y A,B X X X Y 3

229 222 9 A,B X Y Y X 4 5 X Y X Y

230 S Y, Y X 59 Y Y Y Y Y Y X Y Y Y Y Y X Y Y Y Y X X Y Y Y X X Y Y

231 224 9 X Y Y X Y Y Y Y Y Y X Y Y

232 H H MARU

233 ( ) H

234 H

235 228 9 H HA S

236 H1.8, TIG TIG

237 % 8.4%

238 % 25.3%

239

240 co-medical

241 % 48% 6% 6%

242

243 % % 54% 60% 70% 68% % % 53% 18% 20 49

244 GDP 1999 GDP %

245 238 9 WHO

246

247

248 (%)(1993) % % 52.7% 43.6% OECD % % 28.00% 25.90% 24.90% 24.00% 20.80% 20.10% GDP

249

250

251 244 9

252 % A

253

254

255

256 % % % % 98% 62% % 65% 80% 90% 9

257 ACGME Accreditation Council for Graduate Medical Education: ACGME ACGME JAMA

258

259 %

260 :

261 : : :

262 : % * : %

263 : % : % Charles Vincent 1994 The Lancet Why Do People Sue Doctors?: A Study of Patients and Relatives Taking Legal Action Vol.343, solicitor : %

264 : % : % :

265 : % : % : %

266 : % I wanted an explanation. I wanted the doctors to realize what they had done. To get back at the doctor involved. Robyn S. Shapiro 1989 Archives of Internal Medicine A Survey of Sued and Nonsued Physicians and Suing Patients Vol.149, % 22%

267 260 9

268

269 262 9 FAX 3

270 NPO COCODES ADR

271

272

273 %

274 , %

275 % % 2 40 % 3 26 % 4 7% 5 4% 98 %

276

277

278

279

280 N O A 120ml

281

282

283 AERA 2,3

284 (1) (2)

285 278 9

286

287 ,2 ADR Alternative Dispute Resolution ADR mediation ADR ADR mediation)

288 NPO 9 NPO ADR 2 700

289 282 9 ) (1) (2) (3) (4) (5)

290 (1) (2) (3) (4)

291 284 9

292

293 Professional

294 Freedom (1) (2) (3) HMO 1978 (Peer Review Organization) JCAHO(Joint Commission for Accreditation of Healthcare Organization)

295 288 9 JCAHO Exemption Clause Complaint manager & Ombudsman a b. 41 c. d. e. 3 / 4 d. f.

296 /16

297 290 9

298

299 292 9

300

301 294 9

302

303 296 9

304

305

306

307

308 301 A Z ADL 77 AI 88 BSE 120 BST 91 CJD 122 DNA 43 EBM 41 EMA 58 fmri 97 gynecology 66 HIV 66 HLA 62 IC (informed consent) 19 MMR 116 MR Medical Representative 158 PET 97 PTSD 96 QOL 93 SARS 116 SNP 43, 55, 62 SQUID 97 truth telling 32 T 62 vcjd , 23, 40, , , 95, , 53, 61, 70, , 101, 116 MRI , , 153,

309 , 69, 80, 83, , 28, , , 28, , , , , 151, , 43, , 67 39, , 124, , , , 58, , , , ,

310 , , , , 116

311

312 305 2

313 Web tokyomd/gogatsusai2003/ c

医療事故の現状と課題-医療事故への対応策の整備を中心に-

医療事故の現状と課題-医療事故への対応策の整備を中心に- 1 2 1 2 3 1 2 3 1 I II 1 1 1993 5 442 2002 896 10 1 5 14 http://courtdomino2.courts.go.jp/shanyou.nsf/0258b7a1680aa82849256467004875a6/352546364a541 14049256d5c000dde7f?OpenDocument 22% 2 3 4 5 2 6 1997

More information

19 Donabedian 1. 2. 3. 1 1. a s d 2. 3. a s d f 3 1 2 2 a Avedis Donabedian, Quality Improvement through Monitoring Health Care- 1996 s 50 6 1991 458-462 20 3 JCAHO JCAHO JCAHO JCAHO a JCAHO The Joint

More information

2

2 1 2 3 4 5 ( ) 6 7 8 "proteinaceous infectious particles" ( ) (PrP Sc ) (PrP C ) PrP C PrP Sc PrP Sc 9 10 (1) (2) 11 12 13 14 15 16 (1) (2) (3) 17 (4) (5) 18 19 20 21 22 23 24 (1) Creutzfeldt-Jakob - -.

More information

1章

1章 ... 1... 1... 1... 2... 2... 3... 3... 6... 10... 14... 18... 19... 20... 23... 29... 29... 33... 40... 47... 48... 48... 54... 54... 59... 61 ... 63... 65... 65... 66... 66... 69... 71... 107 1 2 3 //

More information

(2009) 1... / 1 ( ) / 1 ( ) / 1 ( ), 2 ( )

(2009) 1... / 1 ( ) / 1 ( ) / 1 ( ), 2 ( ) 212009................................................ 2............................................ 115 (2009) 1... / 1 ( )........................................... 4 2... / 1 ( )......................................

More information

「若年不安定就労・不安定住居者聞取り調査」報告書

「若年不安定就労・不安定住居者聞取り調査」報告書 2008 3 2006 2007 3 19 6 7 5,400 2007 4 5 19 94 1 2 2007 5 i 2007 6 12 100 100 1 2 2008 3 ii 1960 1990 iii = 1990 = = iv 5 5 v & = 2 24 = 1990 10 vi vii i iii 1 3 1.1.............................................

More information

2009年度 東京薬科大学 薬学部 授業計画

2009年度 東京薬科大学 薬学部 授業計画 2009 2 234 Tokyo University of Pharmacy and Life Sciences since 880 Tokyo University of Pharmacy and Life Sciences Department of Clinical Pharmacy Men's Division Department of Clinical Applied Pharmacy

More information

I 01NA AB 4,5,,. (),,,. (),,,,.,..,,.,. 1, ( 2, 1-1, ),,,.. 2 (2-5),,, ( ),. 3 (1): (1-2-2, ),., ( ). 4 (2): ( ), (),. 5

I 01NA AB 4,5,,. (),,,. (),,,,.,..,,.,. 1, ( 2, 1-1, ),,,.. 2 (2-5),,, ( ),. 3 (1): (1-2-2, ),., ( ). 4 (2): ( ), (),. 5 II 01NA002 2.0 1 AB 7,8 1 (1) ( ( ):1-1,1-4-1) 2 (2) ( 2-1) 3 (3) ( 2-1) 4 (4) ()( 2-1) 5 (1) ( 2-2) 6 (2) ( 2-2) 7 ( 2-3) 8 ( 1-4-2,2-4) 9 ( 1-3,1-2) 10 ( 2-5) 10% 30% 60% II( 6 ) (2013 ) () ( 6 ) ( 2015

More information

(1)...3 (2)...5 (3)...6 (4) (1)...9 (2)...10 (3)...13 (4) 14 (5) (1)...16 (2) (1)...21 (2)...22 (3)

(1)...3 (2)...5 (3)...6 (4) (1)...9 (2)...10 (3)...13 (4) 14 (5) (1)...16 (2) (1)...21 (2)...22 (3) ...1...3...3 (1)...3 (2)...5 (3)...6 (4)...7...9 (1)...9 (2)...10 (3)...13 (4) 14 (5)...15...16 (1)...16 (2)...19...21 (1)...21 (2)...22 (3)...24...26...26 (1)...26 (2)...28 (3)...30 (4)...31 (5)...35

More information

. 1 EBM Evidence-Based Medicine JCAHO 2

. 1 EBM Evidence-Based Medicine JCAHO 2 1 1 . 1 EBM Evidence-Based Medicine JCAHO 2 . 2 3 . 4 . 5 . When Where Who What Why How 6 . 7 3 DPC . 20 30 8 20 30 . (1) 9 3 BP mm mm . (2) 10 . http://epath.medis.or.jp/ 11 . 12 . 13 . 14 15 . PDCA Plan

More information

04菊池氏.indd

04菊池氏.indd KIKUCHI Sakae 1 1 1899 32 2000 1966 1.58 1990 1.57 2000.15 2 32 13 2 3 4 18 39.6 25 216,974 106,594 110,380 12 22 5 4.72 12 6 25 33 60 90 25 35 23 24 3 25 7 25 35 45 2 2002.9 4 1925 2003 1997 8 1975 25

More information

安全・安心な社会を目指して―現代社会病理の背景に関する有識者ヒアリングとりまとめ-

安全・安心な社会を目指して―現代社会病理の背景に関する有識者ヒアリングとりまとめ- 1 http://www.esri.go.jp/jp/prj/social/social_main.html 2 3 4 5 I 1990 2 II 16 6 20 3,000 2,136 71.2 16 15 16 20 50 3001 55.9 65.8 64.0 55.6 51.4 50 60 3 4 30 50 40 40 30 30 5 79.4 86.1 67.8 44.6 48.8 41.1

More information

GB 3rd edition final.ppt

GB 3rd edition final.ppt Complementary and Alternative Medicine (National Center for Complementary and Alternative Medicine; NCCAM) Complementary and alternative medicine is a group of diverse medical and health care systems,

More information

untitled

untitled 19 10 24 9 1... 2 2... 2 2-1... 2 2-2... 3 2-3... 3 2-4... 6 3... 7 3-1... 7 3-2... 7 3-3... 8 3-3-1... 8 3-3-2... 9 1... 9 2... 11 3... 13 4... 17 5... 18 3-3-3... 20 1... 20 20... 22 30... 27... 28 3-3-40...

More information

< > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ [ [ [ [ KULASIS

< > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ [ [ [ [ KULASIS < > Introduction to Basic Organic Chemistry 1,2 [ 2 [ 10 11 12 13 14 15 [ [ [ [ KULASIS < > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ 11 12 14 15 [ [ [ [ KULASIS < > Introduction to Basic

More information

1. 3 2. 2 7 3. 10 4. 12 5. 15 6. 18 7. 21 8. 24 9. 28 10. 31 11. 34 12. 38 13. 41 14. 44 15. 47-1 - 16. LET S TRY 50 17. 52 18. 55 19. K 58 20. TAWASHI 62 21. 65 22. 68 23. 72 24. Student Venture Project

More information

医師会将来ビジョン委員会答申「将来の医師会活動及び医療制度のあり方」(2012.3)

医師会将来ビジョン委員会答申「将来の医師会活動及び医療制度のあり方」(2012.3) 2012 3 2011 1 20 1 2 6 3 8 5 12 1 2 茨 1 2011 1 20 2 2011 6 18 3 2011 8 27 28 4 2011 11 5 5 2011 12 17 18 6 2012 2 4 P1 P2 P11 P11 P11 P14 P14 P14 P15 P18 P19 P19 P20 P21 P21 P22 P23 P23 P23 P27 P29 P30

More information

Cover_Page.qxd

Cover_Page.qxd Michael Foley JSDF5 JSDF JSDF JSDF 20052004 12 26 2000 2005 JSDF JSDF 1 JSDF JSDF NGO JSDF JSDF JSDF Preah Vihear JSDF 2002 iii 2004 70 JSDF 2004 12 26 JSDF 2005 8 2005 7JSDF JSDF 2006 JSDF JSDF 2 7400

More information

広域防災拠点検討会報告書030723表紙_0829_.PDF

広域防災拠点検討会報告書030723表紙_0829_.PDF 15 3 i 15 3 ii iii iv ( ) ( ) ( ) ... i...iii... 1.... 1.... 1..... 1..... 2.... 3... 5.... 5..... 5..... 5.... 6..... 6..... 6.... 7..... 7..... 8... 12... 13.... 13..... 13..... 16..... 16.... 17....

More information

NEWS LETTER No.10 (Page 1)

NEWS LETTER No.10 (Page 1) Who When Where What Why How Who When Where What Why How U.S. Department of Agriculture / U.S. Department of Health and Human Services Guide Line PEOPLE'S REPUBLIC OF CHINA GUIDE LINE NORWAY WHO WHEN WHERE

More information

生命倫理100_資料4-7

生命倫理100_資料4-7 26 27 Single cell clones picked from swaps12p36 (18) Single cell clones picked from swaps12p18 (24) 1.3% (p0) 1.1% (p58) 28 29 Outline 30 31 32 33 34 Columbia, The New York Stem Cell Foundation Oocyte

More information

IT Information Technology Information and Communication Technology E mail IT -84-

IT Information Technology Information and Communication Technology E mail IT -84- Protection of personal information and privacy Shinako MATSUI* * 17 19 * -83- IT Information Technology Information and Communication Technology E mail 18 15 17 IT -84- -85- 1980 OECD Guidelines on the

More information

1 1 1 2 2 3 3 4 5 6 6 7 8 8 8 9 10 10 14 16 17 17 18 18 18 23 27 27 27 28 29 29 30 30 31 32 32 33 34 34 35 36 37 38 38

1 1 1 2 2 3 3 4 5 6 6 7 8 8 8 9 10 10 14 16 17 17 18 18 18 23 27 27 27 28 29 29 30 30 31 32 32 33 34 34 35 36 37 38 38 2007 2006 11 29 1 1 1 2 2 3 3 4 5 6 6 7 8 8 8 9 10 10 14 16 17 17 18 18 18 23 27 27 27 28 29 29 30 30 31 32 32 33 34 34 35 36 37 38 38 40 40 40 11 41 41 42 42 43 43 44 45 46 46 47 47 49 50 51 51 52 53

More information

24回日本エイズ学会誌1_ indd

24回日本エイズ学会誌1_ indd 10 ICAAP 11 24 9:40 10:10 1 B1F 1. 10 Myung-Hwan Cho 2. Zahid Hussein President of AIDS Society of Asia and the Pacific ASAP 11 24 13:10 15:40 1 B1F 1 13:10 13:55 PS1-1 ART in the Developing World: Progress

More information

はじめに

はじめに BSE BSE BSE BSE BSE BSE BSE 2 BSE EU BSE BSE 4 student initiative BSE BSEBovine Spongiform Encephalopathy BSE BSE BSE 1 2001 9 10 BSE BSE BSE BSE BSE BSE BSE 1996 BSE BSE BSE BSE BSE BSE BSE BSE BSE BSE

More information

,,,, ( ) 1. 9

,,,, ( ) 1. 9 --I 1A09021 1.0 1 2 AB 1-35,,,, () 20 -- 300 A 100 1 2 3,,,,,, 1 4 13 - [] 2 4 20 - [] 3 4 27 4 5 11 5 5 18 6 5 25 7 6 1 8 6 8 9 6 15,,,, 10 6 22,,,, 11 6 29 ( ) 1. 9 1A10021 1.0 1 2 AB 1.????,. () 200

More information

< E397C C5F8FB4985E2E706466>

< E397C C5F8FB4985E2E706466> 2016 11 2613 00 17 30 2710 00 17 30 2016 Vol.11 Medical Governance Society program 50 50 NPO ( ) IRIS 108-0074 2-12-13-201 Tel; 03-6455-7432, Fax; 03-6455-7505 e-mail; genba-kyougikai@umin.net 11 26 13

More information

4 A) (OECD,2005) 78.4 85.3 (WHO,2002) B) 5 A) B) C) 1 7 2

4 A) (OECD,2005) 78.4 85.3 (WHO,2002) B) 5 A) B) C) 1 7 2 5 2006 9 1 A) 1 2 3 4 B) 1 2 3 4 5 2 A) GDP 7.9 B) 31 25 8 10 1 45 3 31 8 2 70 1 4 A) (OECD,2005) 78.4 85.3 (WHO,2002) B) 5 A) B) C) 1 7 2 1.6 3 31.1 4 2 5 3 4 CT MRI PET 1 30 A) 1 2 6 B) 1 2 3 4 5 3 90.5

More information

< > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ [ [ [ [ KULASIS

< > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ [ [ [ [ KULASIS < > Introduction to Basic Organic Chemistry 1,2 [ 2 [ 10 11 12 13 14 15 [ [ [ [ KULASIS < > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ 11 12 14 15 [ [ [ [ KULASIS < > Introduction to Basic

More information

2

2 1 2 17 1884 2 131 1 1..He lived to serve 2 2 2 2 14,416 104,000 1 QOL Quality of Life 2 21 2013 25 21 3 4 5 QOL 6 QOL QOL 59 1 60 7 QOL QOL 8 2,774 2015 27 5 7 241 2015 27 5 8 12 2015 3 7 58 1,030 113

More information

029 Meg D. Newman Meg D. Newman, MD.: New Developments in HIV Care for Women. From the AIDS Education, the UCSF Positive Health Program, San Francisco General Hospital Medical Center, 995 Potrero Ave c/o

More information

16

16 16 ...1...2...3...5...6...6...6...7...8...9...10...10...11...12...12...13...15...15...16...17...18...19...20...21...21...22...23...24...25...25...26...28...30...31...32...33...33...34 ...35...36...37...38...39...40...40...40...40...40...40...40...41...41...41...41...42...42...42...42...43...43...43...44...44...44...44...45...45...45...46...46...46...47...47...48...49...50

More information

88 1A AB 1.????,. () 200 A 100,,,.. (,, )..,,,,,,,,,,, [], [ ], [ ],,, [ ],, [ ], [],.. 7

88 1A AB 1.????,. () 200 A 100,,,.. (,, )..,,,,,,,,,,, [], [ ], [ ],,, [ ],, [ ], [],.. 7 87 --I 1A09021 1.0 1 2 AB 1-35,,,, () 20 -- 300 A 100 1 2 3,,,,,, 1 4 16 - furukubo-tokunaga.gm@u.tsukuba.ac.jp [] 2 4 23 - [] 3 5 7 kinaba@shimoda.tsukuba.ac.jp 4 5 14 sasakura@kurofune.shimoda.tsukuba.ac.jp

More information

... 1... 2... 3... 5... 6... 6... 6... 7... 8... 9... 10... 10...11... 12... 13... 14... 15... 15... 16... 17... 18... 19... 19... 20... 21... 22... 23... 24... 25... 25... 26... 27... 28... 29... 29...

More information

GDP GDP 1 98% 2

GDP GDP 1 98% 2 2016 2016 4 6 [ ] 1 1.1 1.1.1 1. 2. 3. 2 1 4. 1 700-800 1 GDP GDP 1 98% 2 1.1.2 BOD Biochemical Oxygen Demand BOD COD Chemical Oxygen Demand COD DO DO PM2.5 eg.1 GDP CO 2 eg.2 Life Cycle Assessment 3 eg.

More information

3 2

3 2 1 2016 January No.747 3 2 CONTENTS 2 5 9 10 16 17 18 19 20 26 27 28 Public relations brochure of Higashikawa 1 2016 January No.747 4 HIGASHIKAWA TOWN NEWS 5 HIGASHIKAWA TOWN NEWS HIGASHIKAWA TOWN NEWS

More information

(Travel Medicine) (Emerging Re-emerging Diseases) ) ) ) ) ) ) ) 10 ) 12 ) ) 12 ) 13 ) 14 ) 15 ) 17 ) 18 ) 20 ) 22 24

(Travel Medicine) (Emerging Re-emerging Diseases) ) ) ) ) ) ) ) 10 ) 12 ) ) 12 ) 13 ) 14 ) 15 ) 17 ) 18 ) 20 ) 22 24 1999.No2(22) (Travel Medicine) (Emerging Re-emerging Diseases) ) ) ) ) ) ) ) 10 ) 12 ) ) 12 ) 13 ) 14 ) 15 ) 17 ) 18 ) 20 ) 22 24 Travel Medicine Travel Clinic i) ii) iii) ) 200 Emerging Re-emerging Diseases

More information

untitled

untitled 2003 300 2015 500 2015 2006 quality of lifeqol 2012 2016 5 research guideline training practice 4 QOL QOL 2013 3 7 1 8 2 8 1 22 23 2 3 3 47 1 2 3 4. 49 1 50 2 51 1 2 3 4 3 73 1 2 3 4 5 87 1 88 2 88 1 2

More information

:,, : - 7 -

:,, : - 7 - 31 ~ ~ - 6 - :,, : - 7 - (),,,,,,; ~ ~ *1 *2 6,,,~,,~ - 8-32 ,, ( );( ),,,,,, ~ ~ ~,,,, (),,,,, - 9 - 33 ~*~ ~~ ~, ~ ~ ~ ~ ~, ~~,,,, - 10 - BCG () g ) BCG BCG,, 34 ,,,, (),,,,,,,,,,,,,, () ( 3 90 [7 6

More information

(プロ1特別企画用ショート版) (詳細頁レ).indd

(プロ1特別企画用ショート版) (詳細頁レ).indd Professor, Department of Cardiovascular Medicine Graduate School of Medicine and Faculty of Medicine, The University of Tokyo Ryozo Nagai Former Senior Clinical Advisor, Centers for Medicare & Medicaid

More information

History I COE

History I COE 2008 108-8641 5-9-1 TEL 03-5791-6334FAX 03-5791-6335 e-mailgakufu@lisci.kitasato-u.ac.jp 228-8555 1-15-1 TEL 042-778-9760FAX 042-778-9761 e-mailnyushi@kitasato-u.ac.jp URL http://www.kitasato-u.ac.jp/lisci/index.html

More information

2013. 1 21 21 29 35 1976 1 21 2 36 1976 2 28 37 1976 5 1 38 1976 6 2 13 3 39 1976 7 7 40 1976 9 18 14 1 41 1976 11 6 42 1976 12 10 43 1977 2 25 44 197

2013. 1 21 21 29 35 1976 1 21 2 36 1976 2 28 37 1976 5 1 38 1976 6 2 13 3 39 1976 7 7 40 1976 9 18 14 1 41 1976 11 6 42 1976 12 10 43 1977 2 25 44 197 20 20 Vol. 50No. 1 1 310 1963 2012 1 1963 6 12 WHO 2 1963 7 10 3 1963 9 11 4 1963 10 9 5 1963 11 13 OR 6 1963 12 11 7 1964 2 12 I 8 1964 3 11 9 1964 4 8 II 10 1964 5 13 III 11 1695 6 9 12 1965 7 14 13

More information

笑いの効果ー脳にどんな影響をもたらすか

笑いの効果ー脳にどんな影響をもたらすか 37 NPO NPO OECD Health Data 2005 WHO WHO ( ) J@pan Inc 3 3 2002123 410 1 GNP13.5 50 AHA News Oct.28,1992 3 07.7 2007 31 11 26 1 47.35 2 5.91 3 5.81 63 1.95 192 0.02 10 14 OECD 290 206 127.6 1999 50 (OECD)

More information

. No.1 Copyright: Takahiro Kiu No.1 (UMIN Cente

. No.1 Copyright: Takahiro Kiu No.1 (UMIN Cente . No.1 No.1 No.2 No.3 No.4 No.5 No.6 , No.7 No.8 Research http://www.umin.ac.jp/research/ Education http://www.umin.ac.jp/education/ Multipurpose http://www.umin.ac.jp/multi-purpose/ AC - Academic societies

More information

Core Ethics Vol. Sex Reassignment Surgery SRS SRS GID GID SRS GID GID GID GID GID QOL QOL QOL -- QOL

Core Ethics Vol. Sex Reassignment Surgery SRS SRS GID GID SRS GID GID GID GID GID QOL QOL QOL -- QOL Core Ethics Vol. MTF Gender Identity Disorder GID GID GID GID QOL GID QOL QOL GID QOL GID QOL QOL QOL GID QOL Gender Identity Disorder QOL GID Core Ethics Vol. Sex Reassignment Surgery SRS SRS GID GID

More information

untitled

untitled -1 - 72 DVD 34-2 - 49-3 - 45-4 - OIE BSE 56 OIE BSE 39 BSE 71-5 - 20 30 69-6 - 66-7 - 28-8 - 1 43-9 - 38-10 - 58 46-11 - 69 49 48-12 - 43-13 - 76 35-14 - 43 2 37 2 65 68 CM 57-15 - 19 73 70-16 - - 17 -

More information

老年医学update2007-08

老年医学update2007-08 Geriatric Medicine Update 2007-08 (ISBN978-4-7583-0298-2 C3002) Editor: Journal Publication Committee, The Japan Geriatrics Society 2007. 7. 1 1st ed MEDICAL VIEW, 2007 Printed and Bound in Japan Medical

More information

untitled

untitled 5 K 5 3 HP http://www.mhlw.go.jp/bunya/shakaihosho/iryouseido01/taikou03.html 2004 1 2 1 http://www.dm-net.co.jp/calendar/2007/06/005835.php 6 85cm 100cm 2 90cm 2 TG 150mg/dl HDLHDL-C 40mg/dl 130mmHg 85mmHg

More information

i ii iii iv v vi vii ( ー ー ) ( ) ( ) ( ) ( ) ー ( ) ( ) ー ー ( ) ( ) ( ) ( ) ( ) 13 202 24122783 3622316 (1) (2) (3) (4) 2483 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) 11 11 2483 13

More information

加藤茂孝先生

加藤茂孝先生 Shigetaka KATOW 2009 4 24 WHO 5 9 1 5 16 1 TV 6 12 6 11 WHO 6 4 5 12 E-mail : modern_media@eiken.co.jp 2009. 4. 28. http:idsc.nih.go.jpidwrkanjaweeklygraph01flu.html 0101-0051 - RIKEN Center of Research

More information

14 BSC 15 3

14 BSC 15 3 14 BSC 15 3 BSC 36 Evidence-Based Policy BSC BSC BSC 36 BSC BSC BSC 133 36 25 Spearman 0.5 BSC 3 0.06 36 1 1 2 1 2 7 3 36 1 5 1 23 1 36 2 1 1 3 2 10 1 15 36 23 2 1 36 1 13 4 36 Peer Group 3 BSC BSC BSC

More information

mrna Zc3h12a IL-6

mrna Zc3h12a IL-6 mrna Zc3h12a IL-6 IgG4 The 4th East Asian Group of Rheumatology (EAGOR2011) S3PE CaMK EBM PubMed NHK TBS European Thyroid Journal Nature, Lancet msv ICRP msv msv msv WHO COE sirna M M M VS VS VS

More information

第1回土地改良研修会

第1回土地改良研修会 2006.5.11 26 51 62 8 56 62 6 56 8 3 1-1 - P 1 3 25 1 2 5 2000 3 24 1 2 3 4 1 4 2 2 A4 5 6 2 1961 5 5-2 - 1 1 5 2009 2007 5 3 10 27 8 8 3 3 3 5 10-3 - P 2 3 3 2003 8 29 2003 8 29 3 3 3 2 3 1 1 1 1-4 - 2000

More information

Microsoft Word - H22年度雄勝中央病院卒後臨床研修プログラム.docx

Microsoft Word - H22年度雄勝中央病院卒後臨床研修プログラム.docx 3 2 380 32 1 202,812 11,967 17.2 1,441 129 24 1 6 1 3 1 2 3 50-60 /2 2 2 1-2 2 1 2 2 1 1-2 1 CPC / 4 / / 2 / AED ICLS JPTEC 3 a: b: c: d: 4 c,d a b d 70% 2 10 4 11 12 21 7 21 8 5 Evidence Based Medicine

More information

展示の刹

展示の刹 I Yasunari Abe / 2017 7 1 2017 13 13 1 4 29 7 30 2017 5 9 13 10 3 3 2 1 2017 24 2017 11 004 Summer / May. 2018 / No.416 23 24 2016 10 30 2 2016 12 27 2017 1 41cm WEB 2017 1 15 22 15 11 13 2 2 3 21 3 2

More information

FA

FA 29 28 15 1985 1993 The process of the labor negotiations of the Japan Professional Baseball Players Association, 1985 1993 ABE Takeru Graduate School of Social Science, Hitotsubashi University Abstract

More information

経済教育に関する研究会中間報告書 概要

経済教育に関する研究会中間報告書 概要 ii iii 3 NHK 2 iv 3 4 12 34 1 2002 48 34 17 14 27 4 33 14 2002 31 17 4 4 8 2 (2) ( 8 ) 6%!? 57.7% 10.7% 6% 1 2 3 4 1 2 3 I II III I II III 1 2 3 1 2 200 100 120 3

More information

1 (1996), p. 7 (2006), p (2003), p. 2 p (2003), p. 21 (2008), p. 3 (2003), p. 17 B (2003), p. 28 A, A (2004), p. 17 J, A (2004), p. 9 (p.

1 (1996), p. 7 (2006), p (2003), p. 2 p (2003), p. 21 (2008), p. 3 (2003), p. 17 B (2003), p. 28 A, A (2004), p. 17 J, A (2004), p. 9 (p. ISSN 1347-4448 ISSN 1348-5504 8 12 (2009 12 ) E-mail: h-amikur@sophia.ac.jp I. 1 2009 Global Business Research Center www.gbrc.jp 701 1 (1996), p. 7 (2006), p. 14 3 (2003), p. 2 p. 11 3 (2003), p. 21 (2008),

More information

36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: , 要旨 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visi

36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: , 要旨 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visi 36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: 378 384, 2014 1 2 要旨 1999 2012 10 31 29 26 80 30 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visit time, chronological change はじめに 4 12 23 27 1 Japan

More information

...J......1803.QX

...J......1803.QX 5 7 9 11 13 15 17 19 21 23 45-1111 48-2314 1 I II 100,000 80,000 60,000 40,000 20,000 0 272,437 80,348 82,207 81,393 82,293 83,696 84,028 82,232 248,983 80,411 4,615 4,757 248,434 248,688 76,708 6,299

More information

在外教育施設派遣教員安全対策資料 在外教育施設派遣教員安全対策資料

在外教育施設派遣教員安全対策資料 在外教育施設派遣教員安全対策資料 1. 1. 1.1.1. 1.1.2. 1.1.3. 1.1.4. 1.1.5. 1. 2. 1. 3. 1. 4. 1-1 1-2 1-3 2. 1. 2. 2. 2. 3. 2. 4. 2.4.1. 2.4.2. 2-1 2. 5. 2. 6. 2.6.1. 2.6.2. 2.6.3. 2.6.4. 2.6.5. 2. 7. 2.7.1. 2.7.2. 2.7.3. 2.7.4. 2. 8. 2.

More information

science

science science IT PERSON TO PERSON EU IT IT WHO TV I T Harvard University Brigham and Women s Hospital, Renal Division UCSF CT MRI IT 1 40 17 3 27 Winslow 1949 Impact Factor 50 1 16 1 NIH Samuel W. Cushman

More information

診療ガイドラインのカラクリ

診療ガイドラインのカラクリ EBM EBM 2-3 (evidence-based medicine: EBM) EBM 1 1 1 2 B burden belief bargain barrier A. JAMA EBMer JAMA EBM 3 EBM 3 EBM 3 3 B. peer review Field(IOM) Shaneyfelt ( Guidelines Qualities Assessment Questionnaire:

More information

<836C83628367834A8374834692B2B895F18145706466>

<836C83628367834A8374834692B2B895F18145706466> 1. 30 5 500 2 7 100 2 10 100 2007 4 1 7,200 6,800 7 NPO 1,200 1 12 15 2 1.5 0.5 30 2 24 5 27 16.8 28 2.3 10,500 / 3 3,800 117 2 3 6 6,000 1 1 1 2 2006 1 6, 000 + + 8 30 17 00 7.5 13 2 B2 2. 50 2 3 1 1

More information

PSCHG000.PS

PSCHG000.PS FA X my garden GDP GDP W H O PR P.S. Dr OK a b c d a b c SA RS SA RS MRSAVRE a b SA RS a b c d NHK CCLCXDCDX AM PC ATP ABPC CD CT CT CT AIU GNP W H O Poem VB VB VB VB f AIDS 7 http:w wwprefm iyazakijpfukushiipedefaulthtm

More information

262014 3 1 1 6 3 2 198810 2/ 198810 2 1 3 4 http://www.pref.hiroshima.lg.jp/site/monjokan/ 1... 1... 1... 2... 2... 4... 5... 9... 9... 10... 10... 10... 10... 13 2... 13 3... 15... 15... 15... 16 4...

More information

11 10 712 12 10 21 21 1024 Division of Public Health) ()()( )(Ph.D) 21

11 10 712 12 10 21 21 1024 Division of Public Health) ()()( )(Ph.D) 21 11 10 712 12 10 21 21 1024 Division of Public Health) ()()( )(Ph.D) 21 1 218 2 3 113 218 13 33039 388 29164 30 4929 28 16 413 16 13 5 24 6 1 2 121317 3 1 2 3 4 () () 30,000 (120235) 430() 1 245 3 11121317

More information

2014 STAP Nature T 120

2014 STAP Nature T 120 2017 10 30 1 250 19 150 100 200 119 2014 STAP Nature T 120 STAP scientist community STAP Nature STAP Nature STAP STAP STAP STAP STAP 121 NHK 2006 2002 STAP STAP 2006 STAP 10 STAP 2 1 1 2006 122 2 1911

More information

表紙

表紙 GUIDE 2016 contents documentary 1 GUIDE 2016 7 6 documentary 2 GUIDE 2016 9 8 documentary 3 GUIDE 2016 11 10 GUIDE 2016 feature 1 feature 2 13 12 20 22 24 30 32 34 40 42 44 50 52 54 56 15 14 Admission

More information

IPSJ SIG Technical Report Vol.2011-UBI-30 No /5/ , 1 1 Evaluation on Effect of Presenting False Information for Biological Information Vi

IPSJ SIG Technical Report Vol.2011-UBI-30 No /5/ , 1 1 Evaluation on Effect of Presenting False Information for Biological Information Vi 1 1 1, 1 1 Evaluation on Effect of Presenting False Information for Biological Information Visualization Systems Kenji Nakamura, 1 Takuya Katayama, 1 Tsutomu Terada 1, 1 and Masahiko Tsukamoto 1 Recentry,

More information

E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian

More information

<4D F736F F D B B83578B6594BB2D834A836F815B82D082C88C60202E646F63>

<4D F736F F D B B83578B6594BB2D834A836F815B82D082C88C60202E646F63> 続 失敗百選 サンプルページ この本の定価 判型などは, 以下の URL からご覧いただけます. http://www.morikita.co.jp/books/mid/066771 このサンプルページの内容は, 初版 1 刷発行当時のものです. i 5 41 1 90 203 80 100 18 2009 10 13 19 1 20 A 1 a Z Z ii A 1 H2 H2 LE7 A 1

More information

1937 100 Q&A Q A 6 6 Q&A Q A EBM Q &A Q A 1 100 1 0 Q A WHO 1978 6000 1 2 17. 106 109, 2005., 1998 Q&A Q A C 1986 2 Narrative Based Medicine NBM NBM Q A Q: A 38 AT MD DO DO 1890 DD 2002 2007 3 2007

More information

untitled

untitled CONTENTS 01 02-03 04-05 06-07 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 48-49 50-51 52 01 02 Mishima,Michiaki 03 04 05 06 07 09 10 11

More information

第2巻目次.doc

第2巻目次.doc 2000 10 (BSE) (vcjd) 1996 3 20 BSE 2 Lord Phillips of Worth Matravers Mrs June Bridgeman CB Professor Malcolm Ferguson-Smith FRS 2000 10 i ii 2 ix BSE DNA BSE B S TSE BSE ibse ii iii BSE BSE BSE BSE BSE

More information

C. S2 X D. E.. (1) X S1 10 S2 X+S1 3 X+S S1S2 X+S1+S2 X S1 X+S S X+S2 X A. S1 2 a. b. c. d. e. 2

C. S2 X D. E.. (1) X S1 10 S2 X+S1 3 X+S S1S2 X+S1+S2 X S1 X+S S X+S2 X A. S1 2 a. b. c. d. e. 2 I. 200 2 II. ( 2001) 30 1992 Do X for S2 because S1(is not desirable) XS S2 A. S1 S2 B. S S2 S2 X 1 C. S2 X D. E.. (1) X 12 15 S1 10 S2 X+S1 3 X+S2 4 13 S1S2 X+S1+S2 X S1 X+S2. 2. 3.. S X+S2 X A. S1 2

More information

PMI2005北米大会報告書

PMI2005北米大会報告書 2 3 Metro Toronto Convention Center Toronto, Canada PMI PMI SIG Meeting Paper Presentation PM PM PMI 4 5 8-15 Sep. 2005, Metro Toronto Convention Center, Toronto, Canada 6 7 CEO PM 180,000 PMI BMW PMI

More information

GL改訂_野原班DST.indd

GL改訂_野原班DST.indd Quality of Life QOL HRQL Circulation Journal Vol. 71, Suppl. IV, 2007 1 HRQL ASO ASO ASO ASO 2 Circulation Journal Vol. 71, Suppl. IV, 2007 evidence based medicine a a b A B C,, A Quality of LifeQOL HDL

More information

目次

目次 FAO Animal Health Manual No. 15 RVF A. EMPRES FAO F. EMPRES FAO EMPRES FAO 16 11 2004 PREPARATION OF RIFT VALLEY FEVER CONTINGENCY PLANS William A. Geering Consultant, EMPRES/Infectious Diseases Group,

More information

星医会00表紙.pdf

星医会00表紙.pdf H A,, , ,,, Facebook PSP PSP in situ hybridization New York Bronx Veterans Administration Hospital, Alcohol Research and Treatment Center demanding education e-ducare S. M. McCann Proc. Natl. Acad.

More information

1... 1... 1... 3 2... 4... 4... 4... 4... 4... 6... 10... 11... 15... 30

1... 1... 1... 3 2... 4... 4... 4... 4... 4... 6... 10... 11... 15... 30 1 2420128 1 6 3 2 199103 189/1 1991031891 3 4 5 JISJIS X 0208, 1997 1 http://www.pref.hiroshima.lg.jp/site/monjokan/ 1... 1... 1... 3 2... 4... 4... 4... 4... 4... 6... 10... 11... 15... 30 1 3 5 7 6 7

More information

- 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - 6 Qol Quality of Life - 22 - - 23 - - 24 - 7 8 9-25 - 10 Forest

More information

untitled

untitled 38 2013 ITAA in OSAKA 2013 81517 38 2013 ITAA in OSAKA 2013 815 17 38 2013 ITAA in OSAKA P01 1001 1002 1004 1005 1010 10F 12F 830 900 8 15 8 16 8 17 830 900 915 1000 1100 1200 10001145 1 10001300 9451200

More information

# EBM EBP # 21 50 1 : 1 2000.

# EBM EBP # 21 50 1 : 1 2000. 8020 健 闘 資 料 2000 年 5 月 発 行 フォーラム8020 # EBM EBP # 21 50 1 : 1 2000. 1 1 1 2 2 5 6 6 6 6 8 8 10 11 12 12 14 15 16 17 17 18 18 18 18 19 22 23 25 26 27 28 30 11 18 8020 1994 11 13 1 8020 2 3 4 8020 5 8020

More information

労 働 Health Care Quality Indicators Project - 6 data collection update report (OECD Health Working Paper No. 29) 5-Oct-7 HPV-18 ( 99 HPV 8 HPV 9 B B C

労 働 Health Care Quality Indicators Project - 6 data collection update report (OECD Health Working Paper No. 29) 5-Oct-7 HPV-18 ( 99 HPV 8 HPV 9 B B C 2 3-29 1 1 労 働 Health Care Quality Indicators Project - 6 data collection update report (OECD Health Working Paper No. 29) 5-Oct-7 HPV-18 ( 99 HPV 8 HPV 9 B B C 8 5 >5 1 1 / 1.1.6 Baseline reference (

More information

A. B. C. D. E. GIO SBO, MR Medical representative CRO contract research organization,,, HIV MR MR MR MR MR CRO contract research organization CRA CRO CRA I IV, CBT OSCE CBT computer based testing OSCE

More information

1 Japan Perspectives in Public Health i 49 8 21 ii 18 http://www.scj.go.jp 1819 (RCT) 21 Plan-Do-See iii BSE (quality of life. QOL) 21 iv Japan Perspectives in Public Health EBMevidence-based medicine invisible

More information